Jennifer K. Simpson - Jan 30, 2023 Form 4 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role
President and CEO, Director
Signature
/s/ Joshua L. Colburn, Attorney-in-Fact
Stock symbol
PBLA
Transactions as of
Jan 30, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 03:37 PM
Previous filing
Mar 2, 2022
Next filing
Mar 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBLA Common Stock Purchase +4.44K +129.79% 7.87K Jan 30, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBLA Warrants (right to buy) Purchase $0 +8.89K $0.00 8.89K Jan 30, 2023 Common Stock 8.89K $2.75 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities purchased as one share of common stock and one warrant to purchase two shares of common stock for a combined price of $2.25 per share and warrant.
F2 On or after March 1, 2023, holder may elect an "alternative cashless exercise" pursuant to which they would receive an aggregate number of shares of common stock equal to 75% of the aggregate number of shares that would be issuable upon a cash exercise.